Winship Cancer Institute
Emory University
Atlanta, GA
Accepting patients
QUINTESSENTIAL
Phase 2 Study of BMS-986393, a GPRC5D-directed CART-Cell Therapy, in Participants with Relapsed or Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Phase 2
Accepting patients
QUINTESSENTIAL-2
Phase 3 Clinical Trial Comparing the Safety and Efficacy of BMS-986393 to Standard of Care Regimens in Patients with Relapsed/Refractory Multiple Myeloma
- CAR T Cell
- GPRC5D
- Randomization
- Phase 3
Accepting patients
EXCALIBER - Maintenance
Phase 3 Clinical Trial Comparing Iberdomide VS Lenalidomide as Maintenance Therapy Following Autologous Stem Cell Transplant in Participants with Newly Diagnosed Multiple Myeloma
- CELMoD
- Post-Autologous Stem Cell Transplant
- Randomization
- Phase 3
Accepting patients
DREAMM-10
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 3
Accepting patients
inMMyCAR
A Phase 1 Study to Evaluate the Safety of KLN-1010, a Novel, In Vivo Gene Therapy to Generate Anti-B Cell Maturation Antigen (Anti-BCMA) Chimeric Antigen Receptor-T Cells (CAR-T) in Patients With Relapsed and Refractory Multiple Myeloma
- CAR T Cell
- BCMA
- Phase 1
- Has results
Accepting patients
Personalized Autologous Transplant
Personalized Autologous Transplant for Multiple Myeloma
- Vaccine
- Autologous Stem Cell Transplant
- Phase 1
Accepting patients
MonumenTAL-1
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Bispecific Antibody
- GPRC5D
- Phase 2
Accepting patients
MagnetisMM-20
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1
- Has results
Accepting patients
CERVINO
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study)
- Bispecific Antibody
- BCMA
- Randomization
- Phase 3
Accepting patients
Etentamig (ABBV-383)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
- Bispecific Antibody
- BCMA
- Phase 1/2
2 hidden based on your filters.Show All